Tonix Pharmaceuticals (TNXP) stock gains as the company posts peer-reviewed data for pain drug TNX-102 and new data for mpox ...

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) saw its stock rise 2% after unveiling new preclinical findings for its ...

Single dose vaccination with TNX-801 protects animals from a lethal challenge with monkeypox, the causative agent of mpox TNX ...

Tonix Pharmaceuticals Holding Corp. stock could rally with FDA approval for Tonmya targeting fibromyalgia. Click for more on TNXP stock here.

Tonix Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Read about Tonix Pharmaceuticals Holding Corp (TNXP:XNAS) stock and today's latest news and financial updates.

Clinical-stage biopharmaceutical company Tonix Pharmaceuticals (NASDAQ: TNXP) is gaining significant attention from investors and market participants. The company develops therapies for conditions ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biotechnology company, today ...

Tonix Pharmaceuticals Holding Corp.* Tonix is a fully-integrated biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and ...

Tonix Pharmaceuticals' new drug shows promise in relieving fibromyalgia pain without addiction risk, according to Phase 3 trial results.

TNX-801 is up to 100,000-fold less virulent than live smallpox vaccine strains and a single dose provides robust immunogenicity and protection against mpox and rabbitpox (more than one year) in ...